Methoxetamine: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [pending revision] |
MDElliottMD (talk | contribs) Auto-created stub |
MDElliottMD (talk | contribs) home-claude: Erowid dosing (erowid-claude source; URLs verified; em-dash clean) |
||
| (8 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
{{MedTemplate | {{MedTemplate | ||
| generic | | generic = Methoxetamine | ||
| classes | | brand = | ||
| mechanism | | structure = | ||
| classes = Research material, Dissociative | |||
| mechanism = NMDA antagonist; SERT inhibitor; sigma-1 agonist | |||
| uses = | |||
| starting_dose = | |||
| preparations = | |||
| fda_max = | |||
| routes = | |||
| onset = | |||
| duration = | |||
| halflife = | |||
| bioavailability = | |||
| pregnancy = | |||
| legal = | |||
| intro = | |||
| pharmacokinetics = | |||
| pharmacodynamics = | |||
| indications = | |||
| dosing = | |||
<titration slug="erowid-dose-multi-route" author="erowid-claude" | |||
title="Multi-route dose ladders (Erowid, very tentative)"> | |||
Erowid's dosage documentation for methoxetamine (MXE)<ref | |||
name="erowid-mxe-dose">Erowid. Methoxetamine Dosage. Erowid.org. | |||
https://www.erowid.org/chemicals/methoxetamine/methoxetamine_dose.shtml. | |||
Accessed 2026-05-26.</ref> is marked "very tentative" throughout and | |||
notes that "doses reported by different users vary by a large amount." | |||
'''Insufflated:''' | |||
* Threshold: 5-20 mg; Light: 10-50 mg; Common: 20-60 mg; Strong: 25-100+ mg | |||
'''Oral:''' | |||
* Threshold: 8-20 mg; Light: 10-30 mg; Common: 40-60 mg; Strong: 50-100+ mg | |||
'''Sublingual/buccal:''' | |||
* Threshold: 5-10 mg; Light: 8-25 mg; Common: 15-50 mg; Strong: 40-100+ mg | |||
'''Intramuscular:''' | |||
* Threshold: 3-8 mg; Light: 5-20 mg; Common: 15-30 mg; Strong: 20-80+ mg | |||
Timing data are not provided by Erowid. The wide variability between | |||
users (some report strong effects at 50 mg; others minimal at the | |||
same dose) and Erowid's tentative qualifier should be reflected in | |||
any presentation. | |||
</titration> | |||
| effects = | |||
| interactions = <pharmaInteractions/> | |||
| pregnancy_details = | |||
| monitoring = | |||
| counseling = | |||
| anecdotes = | |||
| seealso = | |||
| references = | |||
}} | }} | ||
[[Category:Research chemicals]] | |||
[[Category:Arylcyclohexylamines]] | |||
[[Category:Dissociatives]] | [[Category:Dissociatives]] | ||
[[Category:Dissociative Anesthetics]] | |||
[[Category:NMDA receptor antagonists]] | |||